BridgeMD
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)
EU CTIS ID: 2025-524819-37-00
What this study is testing
The primary outcome will be the change in OSA severity from baseline to the 6-month follow-up.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥65 years.
- Diagnosis of moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥15 events/h), determined by a home-based sleep apnea test, with clinical indication for active treatment according to the International Consensus Document on OSA (PMID: 33875282)
- Overweight or obesity (body mass index [BMI] ≥27 kg/m²), consistent with recommendations for semaglutide use in individuals with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.
You likely can't join if
- Presence or suspicion of another sleep disorder.
- >50% central apneas or Cheyne–Stokes respiration
- Excessive daytime sleepiness (Epworth Sleepiness Scale ≥18)
- Participation in a weight-loss program
- Inability to adhere to interventions or assessments
- Type 1 or type 2 diabetes.
See the full eligibility criteria
- Age ≥65 years.
- Diagnosis of moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥15 events/h), determined by a home-based sleep apnea test, with clinical indication for active treatment according to the International Consensus Document on OSA (PMID: 33875282)
- Overweight or obesity (body mass index [BMI] ≥27 kg/m²), consistent with recommendations for semaglutide use in individuals with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.
- Presence or suspicion of another sleep disorder.
- >50% central apneas or Cheyne–Stokes respiration
- Excessive daytime sleepiness (Epworth Sleepiness Scale ≥18)
- Participation in a weight-loss program
- Inability to adhere to interventions or assessments
- Type 1 or type 2 diabetes.
- Severe chronic illness (e.g., neoplasia, renal failure, severe COPD, chronic depression).
- Social or geographic limitations affecting adherence.
- Any clinical indication for which continuous positive airway pressure (CPAP) is deemed mandatory by the referring physician.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.